Literature DB >> 21828964

Carbapenem-resistant Klebsiella pneumoniae in post-acute-care facilities in Israel.

Debby Ben-David1, Samira Masarwa, Shiri Navon-Venezia, Hagit Mishali, Ilan Fridental, Bina Rubinovitch, Gill Smollan, Yehuda Carmeli, Mitchell J Schwaber.   

Abstract

OBJECTIVE: To assess the prevalence of and risk factors for carbapenem-resistant Klebsiella pneumoniae (CRKP) carriage among patients in post-acute-care facilities (PACFs) in Israel. DESIGN, SETTING, AND PATIENTS: A cross-sectional prevalence survey was conducted in 12 PACFs. Rectal swab samples were obtained from 1,144 patients in 39 [corrected] wards. Risk factors for CRKP carriage were assessed among the cohort. Next, a nested, matched case-control study was conducted to define individual risk factors for colonization. Finally, the cohort of patients with a history of CRKP carriage was characterized to determine risk factors for continuous carriage.
RESULTS: The prevalence of rectal carriage of CRKP among 1,004 patients without a history of CRKP carriage was 12.0%. Independent risk factors for CRKP carriage were prolonged length of stay (odds ratio [OR], 1.001; P < .001), sharing a room with a known carrier (OR, 3.09; P = .02), and increased prevalence of known carriers on the ward (OR, 1.02; P = .013). A policy of screening for carriage on admission was protective (OR, 0.41; P = .03). Risk factors identified in the nested case-control study were antibiotic exposure during the prior 3 months (OR, 1.66; P = .03) and colonization with other resistant pathogens (OR, 1.64; P = .03). Among 140 patients with a history of CRKP carriage, 47% were colonized. Independent risk factors for continued CRKP carriage were antibiotic exposure during the prior 3 months (OR, 3.05; P = .04), receipt of amoxicillin-clavulanate (OR, 4.18; P = .007), and screening within 90 days of the first culture growing CRKP (OR, 2.9; P = .012).
CONCLUSIONS: We found a large reservoir of CRKP in PACFs. Infection-control policies and antibiotic exposure were associated with patient colonization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21828964     DOI: 10.1086/661279

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  30 in total

1.  Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae.

Authors:  Sarah M Bartsch; Susan S Huang; Kim F Wong; Rachel B Slayton; James A McKinnell; Daniel F Sahm; Krystyna Kazmierczak; Leslie E Mueller; John A Jernigan; Bruce Y Lee
Journal:  J Clin Microbiol       Date:  2016-08-31       Impact factor: 5.948

2.  Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy.

Authors:  Carlo Tascini; Francesco Sbrana; Sarah Flammini; Enrico Tagliaferri; Fabio Arena; Alessandro Leonildi; Ilaria Ciullo; Francesco Amadori; Antonello Di Paolo; Andrea Ripoli; Russell Lewis; Gian Maria Rossolini; Francesco Menichetti
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

Review 3.  Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients.

Authors:  Federico Perez; David Van Duin
Journal:  Cleve Clin J Med       Date:  2013-04       Impact factor: 2.321

Review 4.  Screening for carbapenem-resistant Enterobacteriaceae: Who, When, and How?

Authors:  Sandra S Richter; Dror Marchaim
Journal:  Virulence       Date:  2016-11-04       Impact factor: 5.882

5.  A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae.

Authors:  Karlijn van Loon; Anne F Voor In 't Holt; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

6.  Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network.

Authors:  David van Duin; Federico Perez; Susan D Rudin; Eric Cober; Jennifer Hanrahan; Julie Ziegler; Raymond Webber; Jacqueline Fox; Pamela Mason; Sandra S Richter; Marianne Cline; Geraldine S Hall; Keith S Kaye; Michael R Jacobs; Robert C Kalayjian; Robert A Salata; Julia A Segre; Sean Conlan; Scott Evans; Vance G Fowler; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

7.  An optimized work-flow to reduce time-to-detection of carbapenemase-producing Enterobacteriaceae (CPE) using direct testing from rectal swabs.

Authors:  C O'Connor; M G Kiernan; C Finnegan; M O'Hara; L Power; N H O'Connell; C P Dunne
Journal:  Bioengineered       Date:  2016-08-17       Impact factor: 3.269

8.  Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections.

Authors:  C Hauck; E Cober; S S Richter; F Perez; R A Salata; R C Kalayjian; R R Watkins; N M Scalera; Y Doi; K S Kaye; S Evans; V G Fowler; R A Bonomo; D van Duin
Journal:  Clin Microbiol Infect       Date:  2016-02-03       Impact factor: 8.067

Review 9.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 10.  Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.

Authors:  L Silvia Munoz-Price; Laurent Poirel; Robert A Bonomo; Mitchell J Schwaber; George L Daikos; Martin Cormican; Giuseppe Cornaglia; Javier Garau; Marek Gniadkowski; Mary K Hayden; Karthikeyan Kumarasamy; David M Livermore; Juan J Maya; Patrice Nordmann; Jean B Patel; David L Paterson; Johann Pitout; Maria Virginia Villegas; Hui Wang; Neil Woodford; John P Quinn
Journal:  Lancet Infect Dis       Date:  2013-09       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.